Gut microbiome structure and metabolic activity in inflammatory bowel disease
暂无分享,去创建一个
C. Huttenhower | E. Franzosa | T. Vatanen | H. Vlamakis | Jeffrey A. Porter | R. Xavier | Jingyuan Fu | A. Zhernakova | C. Wijmenga | S. Reinker | L. McIver | C. Clish | R. Weersma | A. B. Hall | Henry J. Haiser | J. Avila-Pacheco | K. Bullock | Himel Mallick | Alexandra Sirota-Madi | N. Fornelos | J. Sauk | Robin G. Wilson | Betsy W. Stevens | Justin M. Scott | K. Pierce | A. Deik | F. Imhann | J. Ávila-Pacheco | Justin Scott | Himel Mallick, PhD, FASA | R. Wilson | Nadine Fornelos | B. Stevens | Kevin Bullock
[1] L. Galland. Magnesium and inflammatory bowel disease. , 1988, Magnesium.
[2] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[3] Joshua M. Stuart,et al. A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules , 2003, Science.
[4] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[5] Atul J. Butte,et al. Systematic survey reveals general applicability of "guilt-by-association" within gene coexpression networks , 2005, BMC Bioinformatics.
[6] G. Mullin,et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease , 1996, Digestive Diseases and Sciences.
[7] P. Mortensen,et al. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate , 1995, Digestive Diseases and Sciences.
[8] T. Langmann,et al. Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. , 2006, Biochimica et biophysica acta.
[9] T. Jaskowski,et al. Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease , 2006, Clinical and Vaccine Immunology.
[10] N. Pace,et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.
[11] Ying Zhang,et al. HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..
[12] I. Wilson,et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. , 2007, Journal of proteome research.
[13] J. Jansson,et al. Metabolomics Reveals Metabolic Biomarkers of Crohn's Disease , 2009, PloS one.
[14] W. R. Wikoff,et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.
[15] W. Lehmann,et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis , 2009, Inflammatory bowel diseases.
[16] J. Doré,et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota , 2009, Inflammatory bowel diseases.
[17] A. Desbois,et al. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential , 2010, Applied Microbiology and Biotechnology.
[18] J. German,et al. Saturated Fats: A Perspective from Lactation and Milk Composition , 2010, Lipids.
[19] H. Sokol,et al. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host , 2010, Current opinion in gastroenterology.
[20] G. Rogler,et al. Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis , 2010, Gut.
[21] P. Vandamme,et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives , 2011, Gut.
[22] E. K. Kemsley,et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. , 2011, Journal of proteome research.
[23] Timothy L. Tickle,et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.
[24] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[25] C. Huttenhower,et al. Metagenomic microbial community profiling using unique clade-specific marker genes , 2012, Nature Methods.
[26] H. Sokol,et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases , 2012, Gut.
[27] W. Garrett,et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis , 2013, Science.
[28] Roger G. Linington,et al. Molecular networking as a dereplication strategy. , 2013, Journal of natural products.
[29] A. De Luca,et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. , 2013, Immunity.
[30] Paul M. Ruegger,et al. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships , 2013, Microbiome.
[31] C. Brocker,et al. PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[32] Timothy L. Tickle,et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. , 2014, The Journal of clinical investigation.
[33] Se Jin Song,et al. The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.
[34] P. Rutgeerts,et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD , 2014, Gut.
[35] Gary D. Wu. Diet, the gut microbiome and the metabolome in IBD. , 2014, Nestle Nutrition Institute workshop series.
[36] C. Huttenhower,et al. Inflammatory bowel disease as a model for translating the microbiome. , 2014, Immunity.
[37] S. Zeissig,et al. Sphingolipids from a Symbiotic Microbe Regulate Homeostasis of Host Intestinal Natural Killer T Cells , 2014, Cell.
[38] U. Günther,et al. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn’s disease and healthy individuals , 2014, Metabolomics.
[39] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[40] Sunhong Kim,et al. Perspectives on the therapeutic potential of short-chain fatty acid receptors , 2014, BMB reports.
[41] R. Knight,et al. Finding the missing links among metabolites, microbes, and the host. , 2014, Immunity.
[42] Andrew H. Van Benschoten,et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. , 2014, Cell host & microbe.
[43] A. Kostic,et al. An integrative view of microbiome-host interactions in inflammatory bowel diseases. , 2015, Cell host & microbe.
[44] W. Sandborn,et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis , 2015, The American Journal of Gastroenterology.
[45] A. Zhernakova,et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics , 2015, BMJ Open.
[46] Peter B. McGarvey,et al. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches , 2014, Bioinform..
[47] Eric Z. Chen,et al. Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. , 2015, Cell host & microbe.
[48] Chao Xie,et al. Fast and sensitive protein alignment using DIAMOND , 2014, Nature Methods.
[49] Cathy H. Wu,et al. UniProt: the universal protein knowledgebase , 2016, Nucleic Acids Research.
[50] D. McKay,et al. Butyrate enhances antibacterial effects while suppressing other features of alternative activation in IL-4-induced macrophages. , 2016, American journal of physiology. Gastrointestinal and liver physiology.
[51] Loubna Abdel Hadi,et al. Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces , 2016, Mediators of inflammation.
[52] Paul M. Ruegger,et al. A Disease-Associated Microbial and Metabolomics State in Relatives of Pediatric Inflammatory Bowel Disease Patients , 2016, Cellular and molecular gastroenterology and hepatology.
[53] R. Xavier,et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands , 2016, Nature Medicine.
[54] C. Huttenhower,et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease , 2016, Gut.
[55] T. Zisman,et al. The microbiota in inflammatory bowel disease: current and therapeutic insights , 2017, Journal of inflammation research.
[56] Ivan V. Protsyuk,et al. Coupling Targeted and Untargeted Mass Spectrometry for Metabolome-Microbiome-Wide Association Studies of Human Fecal Samples. , 2017, Analytical chemistry.
[57] L. Lichtenstein,et al. P478 The current place of probiotics in treatment of pouchitis: systematic review. , 2017, Journal of Crohn's & colitis.
[58] W. D. de Vos,et al. Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease , 2016, Journal of Crohn's & colitis.
[59] D. Artis,et al. Regulation of inflammation by microbiota interactions with the host , 2017, Nature Immunology.
[60] Luke R. Thompson,et al. Species-level functional profiling of metagenomes and metatranscriptomes , 2018, Nature Methods.
[61] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.